133 related articles for article (PubMed ID: 36588500)
1. Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury.
Aprilliano B; Giuliano C; Paxton RA; Edwin SB
Pharmacotherapy; 2023 Feb; 43(2):129-135. PubMed ID: 36588500
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
3. Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
Towers W; Nguyen SN; Ruegger MC; Salazar E; Donahue KR
Ann Pharmacother; 2022 Jun; 56(6):656-663. PubMed ID: 34541895
[TBL] [Abstract][Full Text] [Related]
4. Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
Ahuja T; Yang I; Huynh Q; Papadopoulos J; Green D
Ther Drug Monit; 2020 Oct; 42(5):737-743. PubMed ID: 32433187
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
6. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center.
Wiethorn EE; Harrison S; Weeda ER; Bell CM
Ann Pharmacother; 2022 May; 56(5):541-547. PubMed ID: 34459268
[TBL] [Abstract][Full Text] [Related]
8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
9. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
Smith AR; Dager WE; Gulseth MP
Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of factor Xa inhibitors in low body weight patients.
Tan Y; Hubbard C; Owens H; Pitt J; Giuliano C; Haan B; Breeden T; Sirbu D; Pena K; Haddox T; Edwin SB
Pharmacotherapy; 2024 Feb; 44(2):131-140. PubMed ID: 37926690
[TBL] [Abstract][Full Text] [Related]
11. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
13. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
17. Weight based heparin dosing for thromboembolic disease is associated with earlier anticoagulation in surgical patients.
Levine AR; Laliberte B; Lin H; Stan K; Ladha KS; Kaafarani HM; Lee J
Int J Surg; 2014 Dec; 12(12):1416-9. PubMed ID: 25448664
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism.
Yamaura G; Ito T; Miyaji Y; Ueda N; Nakae Y; Momoo T; Nakano T; Johmura Y; Higashiyama Y; Joki H; Doi H; Takeuchi H; Takahashi T; Koyano S; Yamaguchi S; Yokoyama M; Tanaka F
Thromb Res; 2021 Oct; 206():99-103. PubMed ID: 34454242
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
20. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
